Worldwide demand forAD Therapy currently
0 Million
Validated therapy + diagnostic concept
0+
Human samples
Strong IP portfolio
0
Patent families
Transition into clinicalphase by
0
PAM Theragnostics Navigating the path to Alzheimer's early detection and therapy
About us
PAM Theragnostics - who we are
Established in 2020, we are a biotech startup dedicated to developing the diagnostic tools and therapeutic strategies, aiming to detect early signs of age-related pathologies of the vascular systems, with the focus on Alzheimer's disease, and offer effective interventions to slow their progression. Currently, we are initiating GMP production and anticipate reaching our First-In-Human phase by 2027.
About us Image
Our mission
We develop strategies to strengthen the vascular system to slow down and potentially prevent AD onset.
Learn More →
Our mission Image
Our approach
We learn from the best by studying the population of healthy centenarians from a Cilento region
Learn More →
Our approach Image
Core team
Andreas Bergmann Foto
Andreas Bergmann
Chief Executive Officer
Paul Kaufmann Foto
Paul Kaufmann
Head of Operations
Yulia Ilina Foto
Yulia Ilina
Chief Scientific Officer
Michaela Press Foto
Michaela Press
R&D Scientist
Funding
With this project, PAM Theragnostics aims to develop a preventive therapy for Alzheimer’s Disease (AD). Our goals are the development of easy and reliable tools for early diagnosis and prediction of AD as well as to provide a safe and cost-effective biomarker guided therapy for the Alzheimer patients. Our main focus lies on vascular contributions in AD-development with the PAM enzyme being the main therapeutic target. The preclinical stage of our research and development project is funded by the European Regional Development Fund (Europäischer Fond für regionale Entwicklung – EFRE) and the Federal State of Brandenburg under the ProFIT Brandenburg program (Programm zur Förderung von Forschung, Innovation und Technologien). Grand Nr.: 80256636, 80256637